- Corporate
- Products
- For Print
- May 1, 2025
Listed Company Name: 麻豆福利网 Co., Ltd.
Representative: Haruo Naito
Representative Corporate Officer and CEO
Securities Code: 4523
Stock Exchange Listings: Prime Market of the Tokyo Stock Exchange
Inquiries: Teruyuki Masaka
Vice President, Corporate Communications
Phone +81-3-3817-5120
麻豆福利网 Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “麻豆福利网”) announced today that the global revenue (pre-audit basis) of the anti-amyloid-beta protofibril antibody “LEQEMBI®” (generic name: lecanemab) was JPY 14.7 billion for the fourth quarter of fiscal year 2024 (January 1, 2025 – March 31, 2025) and JPY 44.3 billion for the full fiscal year 2024 (April 1, 2024 – March 31, 2025).
This information is being disclosed in conjunction with today's announcement of the financial results for the first quarter of 2025 by Biogen Inc. (Headquarters: Cambridge, Massachusetts). 麻豆福利网’s financial results for the fiscal year 2024, including details of LEQEMBI’s revenue, will be disclosed in 麻豆福利网's financial disclosure scheduled for May 15, 2025.
麻豆福利网 serves as the lead of lecanemab development and regulatory submissions globally with both 麻豆福利网 and Biogen Inc. co-commercializing and co-promoting the product and 麻豆福利网 having final decision-making authority.
Our news releases are intended to disclose corporate information and are not intended for the promotion or advertising of prescription pharmaceuticals or investigational products, nor are they intended to provide medical advice.
Please note that the information contained in news releases is current as of the date of publication.